Monopar Therapeutics's 15min Chart Shows KDJ Death Cross, Bearish Marubozu

Monopar Therapeutics's 15-minute chart has exhibited a KDJ Death Cross and Bearish Marubozu pattern on August 14, 2025, at 13:30. This indicator suggests a shift in the stock's momentum towards the downside, with potential further decreases in value. Sellers currently control the market, and the bearish momentum is likely to persist.

Title: Monopar Therapeutics: KDJ Death Cross and Bearish Marubozu Indicate Downward Trend

Monopar Therapeutics Inc. (MNPR) has recently experienced significant bearish indicators on its 15-minute chart. On August 14, 2025, at 13:30, the stock exhibited a KDJ Death Cross and a Bearish Marubozu pattern. These technical signals suggest a shift in the stock's momentum towards the downside, with potential further decreases in value.

The KDJ Death Cross, formed when the K line crosses below the D line on the KDJ indicator, is a strong bearish signal. It indicates a potential shift in the stock's momentum towards the downside. The Bearish Marubozu candlestick pattern, characterized by a large body candle with no wicks, reinforces this signal, suggesting that sellers are in control of the market [1].

These developments follow a broader trend of narrowing Bollinger Bands and bearish Marubozu patterns observed in several other stocks, including ASGN and Cushing NextGen [2, 3]. While these technical indicators provide valuable insights into potential stock price movements, it is crucial for investors to consider these signals in conjunction with fundamental analysis and broader market conditions.

Monopar Therapeutics' financial performance has been challenging, with the company reporting a net loss for the second quarter and six months ended June 30, 2025. For the second quarter, the company reported a net loss of USD 2.45 million compared to USD 1.72 million a year ago. Basic loss per share from continuing operations was USD 0.35 compared to USD 0.49 a year ago. Diluted loss per share from continuing operations was USD 0.35 compared to USD 0.49 a year ago. For the six months, net loss was USD 5.08 million compared to USD 3.36 million a year ago. Basic loss per share from continuing operations was USD 0.73 compared to USD 1 a year ago. Diluted loss per share from continuing operations was USD 0.73 compared to USD 1 a year ago [2].

In addition to the technical indicators, several analyst ratings and price targets have been updated recently, providing valuable insights into the potential performance of various stocks. As of July 7, 2025, several notable companies have seen updates to their analyst ratings and price targets, reflecting the evolving opinions of financial experts [1].

Positive Outlook:
- Alnylam Pharma (ALNY) received a "Buy" rating from Jefferies with a price target of $384.00 [1].
- Chime Financial (CHYM) was initiated with an "Overweight" rating by multiple firms, including Morgan Stanley and Barclays, with targets ranging from $39.00 to $40.00 [1].
- CryoPort (CYRX) was rated "Buy" by BTIG Research with a price target of $10.00 [1].
- Datadog (DDOG) had its price target raised from $150.00 to $175.00 by Bank of America, reiterating a "Buy" rating [1].
- Energy Transfer (ET) was initiated with a "Buy" rating by TD Cowen with a price target of $22.00 [1].
- Grab (GRAB) was rated "Buy" by Jefferies with a price target of $5.70, indicating a 20.94% upside [1].
- Home Depot (HD) was rated "Buy" by TD Cowen with a price target of $470.00 [1].
- Intuit (INTU) was rated "Buy" by Morgan Stanley with a price target of $900.00 [1].
- JPMorgan Chase & Co. (JPM) had a $298.00 target set by Evercore ISI with an "Outperform" rating [1].
- Kinder Morgan (KMI) was initiated with a "Buy" rating by TD Cowen [1].
- Lam Research (LRCX) had its "Buy" rating reiterated by Citigroup [1].
- MACOM Technology Solutions (MTSI) had its target raised from $136.00 to $154.00 by Truist Financial, maintaining a "Buy" rating [1].
- Monopar Therapeutics (MNPR) was initiated with an "Overweight" rating by Cantor Fitzgerald and a target of $74.00 [1].
- Norwegian Cruise Line (NCLH) received a "Buy" rating from Jefferies with a price target of $29.00 [1].
- Oracle (ORCL) received a "Buy" rating from UBS with a $250.00 target [1].
- Oportun Financial (OPRT) was rated "Buy" at B. Riley Financial with an $11.00 price target [1].
- Ovintiv (OVV) was rated "Buy" at Barclays Capital with a price target of $55.00 [1].
- Phibro Animal Health (PAHC) was upgraded at JPMorgan Chase from Neutral to Overweight, with the price target raised from $25.00 to $35.00 [1].
- Progressive (PGR) was downgraded by Morgan Stanley from Overweight to Equal Weight, with a price target of $290.00 [1].
- Pulse Biosciences (PLSE) was initiated by Oppenheimer with an "Outperform" rating and a $22.00 price target [1].
- PTC (PTC) had its Overweight rating reiterated by KeyCorp Bank [1].
- Rockwell Automation (ROK) was initiated by CICC Research with a "Buy" rating and a price target of $320.00 [1].

References:
[1] https://www.ainvest.com/news/cid-15min-chart-signals-bearish-trend-bollinger-bands-narrowing-k
[2] https://www.marketscreener.com/news/monopar-therapeutics-inc-reports-earnings-results-for-the-second-quarter-and-six-months-ended-june-ce7c51dadb8cf726
[3] https://www.ainvest.com/news/crescent-15-minute-chart-shows-bollinger-bands-narrowing-bearish-marubozu-2508-83/